Compare Inovio Pharmaceuticals Inc (INO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 62.7× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is more actively traded (3,201,278 versus 2,350,550). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| INO | SGOL | |
|---|---|---|
Market Cap | $112.19M | $7.03B |
Volume | 3,201,278 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.60 | $51.41 |
52-Week Low | $0.66 | $37.54 |
Typical Hold Time | 43 Days | 57 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
SGOL trades at $39.31, up 0.74% today, while technical indicators show a bearish bias with moving averages and ADX signaling sell conditions. The stock lacks key financial ratio data such as P/E and P/B, limiting fundamental clarity. Recent gold-related news highlights pressure from rising Treasury yields and a firm dollar, though softer inflation data has provided some support.
The outlook remains cautious due to macroeconomic headwinds and incomplete financial disclosures. Risks include interest rate sensitivity and gold price volatility. Investors should seek updated SEC filings for fundamental metrics before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
